The Acute coronary syndrome pipeline therapeutics pipeline is expected to increase on account of increasing population, which are at risk of severe cardiovascular disease. High blood pressure, uncontrollable blood sugar level, hypercholesterolemia, smoking are the main causes of developing acute coronary syndrome. Sometimes, stroke, emotional trauma also make a platform for emerging abnormalities in cardiovascular system. Amendments in lifestyle, routine and habit makes a big difference for increasing continuum of cardiovascular disease. Cumulative growth of pipeline is expected to grow as long as the arena of morbidities due to cardiovascular disease is occurring. In 2009, around 18% of men and 23% of women in United States were at risk of myocardial infarction, accordingly American Heart Association. Increasing the hospital therapy cost also a floating factor for expanding pipeline growth of acute coronary syndrome because it is a make-up of many diseases like myocardial ischemia, unstable angina, myocardial infarction etc.
The acute coronary syndrome is a collection of symptoms associated with myocardial ischemia, non—ST-segment elevation myocardial infarction, unstable angina and ST-segment elevation myocardial infarction. The diagnosis of non—ST-segment elevation myocardial infarction can be complete when ischemia become very severe to cause myocardial damage which leads to release of biomarkers of myocardial necrosis. Atherosclerosis can also occur in severe condition and plaque formation always progresses inexorably all over the person’s lifetime. The risk factors like smoking, diabetes, hypercholesterolemia and hypertension usually harm the blood vessels and which can give consequence such as, endothelial dysfunction.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/acute-coronary-syndrome-therapeutics-pipeline-analysis/toc-sample
In June 2015, Sun Pharmaceutical Industries Ltd. and AstraZeneca Pharma India Limited (AZPIL) have entered into a distribution services agreement in India for AstraZeneca’s brand “Axcer”, a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand under the trademark “Brilinta”, for ticagrelor molecule, which was launched and marketed by AZPIL in India since 2012.
Some of the companies having a pipeline of acute coronary syndrome therapeutics include, Roche Molecular Systems, Inc, MedImmune, LLC, AstraZeneca Plc, SIS Medical AG, Asklepion Pharmaceuticals, LLC, Genentech, Inc., GlaxoSmithKline plc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)